Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia

E. Pazzucconi, L. Mannucci, L. Mussoni, G. Gianfranceschi, P. Maderna, P. Werba, G. Franceschini, C. R. Sirtori, Elena Tremoli

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The effects of bezafibrate 400 mg/day (slow release formulation) on plasma lipids/lipoproteins and on selected haemostatic parameters were evaluated in a double blind cross-over study in patients with Type IIb and IV hyperlipoproteinaemia. Placebo treatment did not influence any of those parameters, but the drug significantly reduced plasma triglycerides (-45%) and VLDL cholesterol, as well as causing a 12 % fall in total cholesterol and a 20 % increase in HDL cholesterol. Apo AI levels were significantly increased following bezafibrate and Apo B was reduced by about 20 %. In addition to changes in the plasma lipid profile, bezafibrate reduced the sensitivity of platelets to the aggregatory effect of collagen, with no effect on TXB2 production. Fibrinogen levels after bezafibrate treatment were significantly lowered, the effect being more marked in patients with hyperfibrinogenaemia. Bezafibrate did not influence the plasma fibrinolytic profile. It is concluded that bezafibrate, besides its beneficial effects on the plasma lipoprotein profile, can exert beneficial changes on specific haemostatic parameters.

Original languageEnglish
Pages (from-to)219-223
Number of pages5
JournalEuropean Journal of Clinical Pharmacology
Volume43
Issue number3
DOIs
Publication statusPublished - Sep 1992

Fingerprint

Bezafibrate
Hypertriglyceridemia
Fibrinogen
Blood Platelets
Lipids
Hemostatics
Lipoproteins
Hyperlipoproteinemia Type IV
VLDL Cholesterol
Hyperlipoproteinemia Type II
Apolipoprotein A-I
Apolipoproteins B
Cross-Over Studies
HDL Cholesterol
Collagen
Cholesterol
Placebos
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bezafibrate
  • fibrinogen
  • fibrinolysis
  • Hyperlipoproteinaemia
  • plasma lipids
  • platelet aggregation

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. / Pazzucconi, E.; Mannucci, L.; Mussoni, L.; Gianfranceschi, G.; Maderna, P.; Werba, P.; Franceschini, G.; Sirtori, C. R.; Tremoli, Elena.

In: European Journal of Clinical Pharmacology, Vol. 43, No. 3, 09.1992, p. 219-223.

Research output: Contribution to journalArticle

Pazzucconi, E, Mannucci, L, Mussoni, L, Gianfranceschi, G, Maderna, P, Werba, P, Franceschini, G, Sirtori, CR & Tremoli, E 1992, 'Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia', European Journal of Clinical Pharmacology, vol. 43, no. 3, pp. 219-223. https://doi.org/10.1007/BF02333013
Pazzucconi, E. ; Mannucci, L. ; Mussoni, L. ; Gianfranceschi, G. ; Maderna, P. ; Werba, P. ; Franceschini, G. ; Sirtori, C. R. ; Tremoli, Elena. / Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. In: European Journal of Clinical Pharmacology. 1992 ; Vol. 43, No. 3. pp. 219-223.
@article{97cbfb5d5802461f99d2c93f0cfe27b4,
title = "Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia",
abstract = "The effects of bezafibrate 400 mg/day (slow release formulation) on plasma lipids/lipoproteins and on selected haemostatic parameters were evaluated in a double blind cross-over study in patients with Type IIb and IV hyperlipoproteinaemia. Placebo treatment did not influence any of those parameters, but the drug significantly reduced plasma triglycerides (-45{\%}) and VLDL cholesterol, as well as causing a 12 {\%} fall in total cholesterol and a 20 {\%} increase in HDL cholesterol. Apo AI levels were significantly increased following bezafibrate and Apo B was reduced by about 20 {\%}. In addition to changes in the plasma lipid profile, bezafibrate reduced the sensitivity of platelets to the aggregatory effect of collagen, with no effect on TXB2 production. Fibrinogen levels after bezafibrate treatment were significantly lowered, the effect being more marked in patients with hyperfibrinogenaemia. Bezafibrate did not influence the plasma fibrinolytic profile. It is concluded that bezafibrate, besides its beneficial effects on the plasma lipoprotein profile, can exert beneficial changes on specific haemostatic parameters.",
keywords = "Bezafibrate, fibrinogen, fibrinolysis, Hyperlipoproteinaemia, plasma lipids, platelet aggregation",
author = "E. Pazzucconi and L. Mannucci and L. Mussoni and G. Gianfranceschi and P. Maderna and P. Werba and G. Franceschini and Sirtori, {C. R.} and Elena Tremoli",
year = "1992",
month = "9",
doi = "10.1007/BF02333013",
language = "English",
volume = "43",
pages = "219--223",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia

AU - Pazzucconi, E.

AU - Mannucci, L.

AU - Mussoni, L.

AU - Gianfranceschi, G.

AU - Maderna, P.

AU - Werba, P.

AU - Franceschini, G.

AU - Sirtori, C. R.

AU - Tremoli, Elena

PY - 1992/9

Y1 - 1992/9

N2 - The effects of bezafibrate 400 mg/day (slow release formulation) on plasma lipids/lipoproteins and on selected haemostatic parameters were evaluated in a double blind cross-over study in patients with Type IIb and IV hyperlipoproteinaemia. Placebo treatment did not influence any of those parameters, but the drug significantly reduced plasma triglycerides (-45%) and VLDL cholesterol, as well as causing a 12 % fall in total cholesterol and a 20 % increase in HDL cholesterol. Apo AI levels were significantly increased following bezafibrate and Apo B was reduced by about 20 %. In addition to changes in the plasma lipid profile, bezafibrate reduced the sensitivity of platelets to the aggregatory effect of collagen, with no effect on TXB2 production. Fibrinogen levels after bezafibrate treatment were significantly lowered, the effect being more marked in patients with hyperfibrinogenaemia. Bezafibrate did not influence the plasma fibrinolytic profile. It is concluded that bezafibrate, besides its beneficial effects on the plasma lipoprotein profile, can exert beneficial changes on specific haemostatic parameters.

AB - The effects of bezafibrate 400 mg/day (slow release formulation) on plasma lipids/lipoproteins and on selected haemostatic parameters were evaluated in a double blind cross-over study in patients with Type IIb and IV hyperlipoproteinaemia. Placebo treatment did not influence any of those parameters, but the drug significantly reduced plasma triglycerides (-45%) and VLDL cholesterol, as well as causing a 12 % fall in total cholesterol and a 20 % increase in HDL cholesterol. Apo AI levels were significantly increased following bezafibrate and Apo B was reduced by about 20 %. In addition to changes in the plasma lipid profile, bezafibrate reduced the sensitivity of platelets to the aggregatory effect of collagen, with no effect on TXB2 production. Fibrinogen levels after bezafibrate treatment were significantly lowered, the effect being more marked in patients with hyperfibrinogenaemia. Bezafibrate did not influence the plasma fibrinolytic profile. It is concluded that bezafibrate, besides its beneficial effects on the plasma lipoprotein profile, can exert beneficial changes on specific haemostatic parameters.

KW - Bezafibrate

KW - fibrinogen

KW - fibrinolysis

KW - Hyperlipoproteinaemia

KW - plasma lipids

KW - platelet aggregation

UR - http://www.scopus.com/inward/record.url?scp=0026714027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026714027&partnerID=8YFLogxK

U2 - 10.1007/BF02333013

DO - 10.1007/BF02333013

M3 - Article

C2 - 1425883

AN - SCOPUS:0026714027

VL - 43

SP - 219

EP - 223

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 3

ER -